Pri­vate eq­ui­ty firm taps ex-Ed­i­tas CEO Jim Mullen to help ex­pand phar­ma port­fo­lio — with a nod to cell, gene ther­a­pies

Jim Mullen is lend­ing his years of biotech CEO ex­pe­ri­ence — from Bio­gen, Patheon and Ed­i­tas — to the pri­vate eq­ui­ty firm Ad­vent In­ter­na­tion­al.

Ad­vent man­ag­ing part­ner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER